River Road Asset Management LLC Grows Position in Royalty Pharma plc (NASDAQ:RPRX)

River Road Asset Management LLC increased its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 9.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 469,980 shares of the biopharmaceutical company’s stock after acquiring an additional 41,918 shares during the quarter. River Road Asset Management LLC owned approximately 0.08% of Royalty Pharma worth $13,296,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Xponance Inc. lifted its stake in Royalty Pharma by 1.9% in the second quarter. Xponance Inc. now owns 31,704 shares of the biopharmaceutical company’s stock worth $836,000 after acquiring an additional 606 shares during the period. EverSource Wealth Advisors LLC lifted its position in shares of Royalty Pharma by 32.1% during the second quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 655 shares during the last quarter. Values First Advisors Inc. lifted its position in shares of Royalty Pharma by 7.6% during the third quarter. Values First Advisors Inc. now owns 10,412 shares of the biopharmaceutical company’s stock valued at $295,000 after buying an additional 738 shares during the last quarter. Phillips Wealth Planners LLC lifted its position in shares of Royalty Pharma by 10.2% during the third quarter. Phillips Wealth Planners LLC now owns 8,733 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 808 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. lifted its position in shares of Royalty Pharma by 10.8% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 9,097 shares of the biopharmaceutical company’s stock valued at $276,000 after buying an additional 887 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX opened at $27.54 on Wednesday. Royalty Pharma plc has a twelve month low of $25.20 and a twelve month high of $31.66. The company’s 50 day moving average is $27.95 and its 200 day moving average is $27.56. The company has a current ratio of 9.35, a quick ratio of 9.35 and a debt-to-equity ratio of 0.78. The company has a market cap of $16.34 billion, a PE ratio of 24.37, a price-to-earnings-growth ratio of 3.99 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.01. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. The company had revenue of $537.00 million for the quarter, compared to the consensus estimate of $600.83 million. During the same quarter in the prior year, the company earned $0.85 EPS. On average, sell-side analysts forecast that Royalty Pharma plc will post 4.05 EPS for the current year.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $0.21 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $0.84 annualized dividend and a yield of 3.05%. Royalty Pharma’s dividend payout ratio (DPR) is presently 74.34%.

Wall Street Analysts Forecast Growth

Several analysts have commented on RPRX shares. The Goldman Sachs Group increased their price target on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday. Morgan Stanley upped their price objective on shares of Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, July 11th. Finally, Citigroup cut their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, October 25th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $41.67.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.